€0.52
Your prediction
Tempramed Technologies Ltd. Stock
Pros and Cons of Tempramed Technologies Ltd. in the next few years
Pros
Cons
News
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership.
Vancouver, BC – December
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, BC – December 5, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and

